BioMimetic Therapeutics to Report 2008 Second Quarter Financial Results on August 11; Company to Release Results of Augment Injectable Bone Graft in Foot and Ankle Fusions
Franklin, Tenn. – August 6, 2008 - BioMimetic Therapeutics, Inc. (NASDAQ: BMTI) today announced that the Company plans to release its financial results for the three months ended June 30, 2008, on Monday, August 11, 2008 after the close of the market. In addition, the Company intends to release results from a pilot clinical study evaluating Augment Injectable Bone Graft in foot and ankle fusions. The Company will host a conference call and audio webcast to discuss these results at 4:30 EDT the same afternoon.
Dr. Samuel E. Lynch, president and CEO, and members of the Company's management team will host the call to discuss the Company's second quarter financial results and product development programs and business activities. Further, the Company's lead Canadian investigator, Timothy R. Daniels, M.D., will also be available on the call to answer questions related to the data released for Augment Injectable in foot and ankle fusion indications.
The conference call may be accessed on August 11, 2008 by dialing 888.680.0878 (passcode: 74937851). The international dial in number is 617-213-4855, and the same passcode applies. You may also pre-register for the call at https://www.theconferencingservice.com/prereg/key.process?key=P7H9LFELB.
A live webcast of the conference call will be available on the Investor Relations section of BioMimetic's website at www.biomimetics.com. The webcast will be archived for at least 30 days following the call.
About BioMimetic Therapeutics
BioMimetic Therapeutics, Inc. is developing and commercializing bio-active recombinant protein-device combination products for the healing of musculoskeletal injuries and disease, including orthopedic, spine and sports injury applications. BioMimetic received marketing approval from the FDA in 2005 for its first product, GEM 21S, for regeneration of bone and periodontal tissue loss resulting from periodontal disease. Currently, the Company has clinical trials ongoing with its product candidates Augment™ Bone Graft (formerly GEM OS1 Bone Graft) and Augment™ Injectable Bone Graft (formerly GEM OS2 Injectable Bone Graft) in multiple orthopedic bone healing indications including the treatment of foot and ankle fusions and the stimulation of healing of fractures of the wrist. The Company's lead product candidates all combine recombinant human platelet-derived growth factors (rhPDGF-BB) with tissue specific scaffolds to actively stimulate tissue healing and regeneration.
GEM 21S® is a registered trademark of Luitpold Pharmaceuticals, Inc., who owns and markets that product through its Osteohealth Company division.
For further information, visit www.biomimetics.com or contact Kearstin Patterson, associate director of corporate communications, at 615-236-4419.
###
Back to Headlines |
